Antimuscarinic Anticholinergic Medications in Parkinson Disease: To Prescribe or Deprescribe?-Reference-Cited by-同舟云学术

Antimuscarinic Anticholinergic Medications in Parkinson Disease: To Prescribe or Deprescribe?

Published:2021-10-08 Issue:8 Volume:8 Page:1181-1188
ISSN:2330-1619
Container-title:Movement Disorders Clinical Practice
language:en
Short-container-title:Mov Disord Clin Pract

Author:

Barrett Matthew J.¹^ORCID,Sargent Lana²³⁴⁵,Nawaz Huma¹,Weintraub Daniel⁶⁷⁸^ORCID,Price Elvin T.³⁴⁵,Willis Allison W.⁶⁹¹⁰

Affiliation:

1. Department of Neurology Virginia Commonwealth University Richmond Virginia USA

2. School of Nursing Virginia Commonwealth University Richmond Virginia USA

3. Department of Pharmacotherapy and Outcomes Science, School of Pharmacy Virginia Commonwealth University Richmond Virginia USA

4. Geriatric Pharmacotherapy Program, School of Pharmacy Virginia Commonwealth University Richmond Virginia USA

5. Institute for Inclusion Inquiry and Innovation (iCubed): Health and Wellness in Aging Populations Core Richmond Virginia USA

6. Department of Neurology University of Pennsylvania School of Medicine Philadelphia Pennsylvania USA

7. Parkinson's Disease Research, Education and Clinical Center Corporal Michael J. Crescenz VA Medical Center Philadelphia Pennsylvania USA

8. Department of Psychiatry University of Pennsylvania School of Medicine Philadelphia Pennsylvania USA

9. Center for Pharmacoepidemiology Research and Training, Department of Epidemiology University of Pennsylvania School of Medicine Philadelphia Pennsylvania USA

10. Department of Biostatistics, Epidemiology and Informatics University of Pennsylvania School of Medicine Philadelphia Pennsylvania USA

Funder

National Institute of Neurological Disorders and Stroke

Publisher

Wiley

Subject

Clinical Neurology,Neurology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/mdc3.13347

Reference84 articles.

1. Parkinson's disease: drug therapy;Oertel WH;Baillieres Clin Neurol,1997

2. Guidelines for the management of Parkinson's disease. The Parkinson's Disease Consensus Working Group;Bhatia K;Hosp Med,1998

3. Anticholinergic burden in Parkinson’s disease inpatients

4. Trends in inpatient antiparkinson drug use in the USA, 2001–2012

5. Atropinic (Anticholinergic) Burden in Parkinson's Disease

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Attitudes and beliefs towards medication burden and deprescribing in Parkinson disease;BMC Neurology;2024-09-06

2. “Starting to think that way from the start”: approaching deprescribing decision-making for people accessing palliative care - a qualitative exploration of healthcare professionals views;BMC Palliative Care;2024-09-06

3. A comprehensive review and recent advancement in the application of tannins for treating Parkinson disease;Pharmacological Research - Modern Chinese Medicine;2024-09

4. Revolutionizing our understanding of Parkinson’s disease: Dr. Heinz Reichmann’s pioneering research and future research direction;Journal of Neural Transmission;2024-08-07

5. Role of the globus pallidus in motor and non-motor symptoms of Parkinson’s disease;Neural Regeneration Research;2024-06-03